Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 9,364 matching trials from the live ClinicalTrials.gov search.

Filters: Portland, Oregon Clear all

Conditions: Parkinson's Disease, Depression
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 35 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer
Interventions: brachytherapy, iodine I 125, radiation therapy; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 236
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more

Conditions: Chronic Sinusitis, Nasal Polyps
Interventions: S8 Sinus Implant, Sham procedure, Mometasone furoate nasal spray; Drug · Procedure
Lead sponsor: Intersect ENT; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 19
States / cities: Atherton, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: NSCLC, Stage I
Interventions: Pembrolizumab; Drug
Lead sponsor: Greg Durm, MD; Other
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 13
States / cities: Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more

Conditions: Metastatic Colorectal Cancer
Interventions: mFOLFOX6, MVA-BN-CV301, FPV-CV301, Nivolumab; Drug · Biological
Lead sponsor: Patrick Boland; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Westwood, Kansas + 4 more

Conditions: Migraine
Interventions: Ubrogepant 100 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more

Conditions: Solitary Osseous Plasmacytoma
Interventions: ixazomib, lenalidomide, dexamethasone, zoledronic acid; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 388
States / cities: Anchorage, Alaska • Burbank, California • Clovis, California + 267 more

Conditions: Social Phobia
Interventions: AV608; Drug
Lead sponsor: Avera Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 15
States / cities: Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 11 more

Conditions: Multiple Sclerosis
Interventions: Methylphenidate, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 20 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: formoterol fumarate inhalation solution; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 16 more

Conditions: Breast Cancer
Interventions: educational intervention, therapeutic dietary intervention; Other · Procedure
Lead sponsor: Institute for Cancer Prevention (IFCP); Other
Eligibility: 48 Years to 78 Years · Female only
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Retinitis Pigmentosa
Interventions: Phase 1b/2: Cohort 1 - OCT-980 Tablet, Phase 1b/2: Cohort 2 - OCT-980 Tablet, Phase 1b/2: Cohort 3 - OCT-980 Tablet, Phase 1b/2: Cohort 4 - OCT-980 Tablet, Phase 1b/2: Cohort 5 - OCT-980 Tablet; Drug
Lead sponsor: Octant, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Portland, Oregon • Dallas, Texas

Conditions: Childhood Malignant Neoplasm
Interventions: Cognitive Assessment, Quality-of-Life Assessment; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Month and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 163
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 119 more

Conditions: Breast Reconstruction, Revision Breast Reconstruction
Interventions: Mentor Larger Size MemoryGel Ultra High Profile Breast Implant; Device
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 30
States / cities: Montgomery, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more

Conditions: Right Ventricular (RV) Dysfunction
Interventions: Right-sided ventricular assist device; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 23 more

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: BAF312, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 52
States / cities: Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: radiation therapy; Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 20 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 127
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 109 more

Conditions: Solid Tumors
Interventions: Tomivosertib (eFT-508); Drug
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Avelumab, Talazoparib, Talazoparib Tosylate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 325
States / cities: Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more

Conditions: Breast Cancer
Interventions: BCG vaccine, CD80 breast cancer vaccine, sargramostim; Biological
Lead sponsor: Providence Cancer Center, Earle A. Chiles Research Institute; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Allergic Rhinitis
Interventions: BDP Nasal Aerosol, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 63
States / cities: Hot Springs, Arkansas • Costa Mesa, California • Downey, California + 50 more

Search by objective public record fields.

Cognitive Behavioral Therapy for Depression in Parkinson's Disease

External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer

Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder

Methylphenidate to Improve Balance and Walking in MS

Study in Subjects Greater Than 40 Years of Age With COPD

Nutrition Intervention in Treating Women With Breast Cancer

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction

Impella RP Flex with Smart Assist

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Radiation Therapy in Treating Young Patients With Gliomas

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)